| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Multiple targets: inflammatory mediators (NF-κB, COX-2, iNOS, TNF-α, IL-1β, IL-6); antioxidant pathways (Nrf2/HO-1); neuroprotective targets.
|
|---|---|
| ln Vitro |
Lactiflorin exhibits anti-inflammatory activity by inhibiting NF-κB activation and reducing the production of pro-inflammatory mediators such as COX-2, iNOS, TNF-α, IL-1β, and IL-6. It has antioxidant activity by activating the Nrf2/HO-1 pathway and scavenging free radicals. The compound shows hepatoprotective effects by reducing liver enzyme levels and improving liver histopathology. It also has neuroprotective effects and immunomodulatory activity, regulating T-cell and macrophage function.
|
| ln Vivo |
In vivo studies of lactiflorin have demonstrated its anti-inflammatory effects in animal models of inflammation, including carrageenan-induced paw edema and LPS-induced sepsis. It shows hepatoprotective effects in models of liver injury (e.g., CCl₄-induced, alcohol-induced). Neuroprotective effects have been demonstrated in models of neurodegenerative diseases. Immunomodulatory effects have been observed in models of autoimmune diseases and allergic reactions. The compound is orally active and has favorable pharmacokinetic properties.
|
| Enzyme Assay |
Anti-inflammatory activity is assessed by measuring the inhibition of COX-2, iNOS, or cytokine production in enzyme assays or cell-based systems. NF-κB activation is measured by reporter gene assays or Western blot analysis of p65 nuclear translocation. Antioxidant activity is assessed by DPPH, ABTS, FRAP, or ROS scavenging assays. Nrf2/HO-1 pathway activation is assessed by Western blot or qPCR. Hepatoprotective activity is assessed by measuring liver enzyme levels (ALT, AST) in cell-based or in vitro assays.
|
| Cell Assay |
Macrophage cell lines (e.g., RAW 264.7) are stimulated with LPS to induce inflammation, and cells are treated with lactiflorin at various concentrations. Inflammatory mediators (NO, TNF-α, IL-1β, IL-6) in culture supernatant are measured by Griess reagent or ELISA. NF-κB and Nrf2/HO-1 pathway activation are assessed by Western blot. For hepatoprotective studies, primary hepatocytes or HepG2 cells are treated with hepatotoxic agents (e.g., CCl₄, APAP) with or without lactiflorin, and cell viability and enzyme levels are measured.
|
| Animal Protocol |
In vivo studies use rodent models. For anti-inflammatory studies, carrageenan-induced paw edema or LPS-induced sepsis models are used. For hepatoprotective studies, CCl₄- or alcohol-induced liver injury models are used. For neuroprotective studies, models of Parkinson's disease, Alzheimer's disease, or cerebral ischemia are used. The compound is administered orally, intraperitoneally, or intravenously. Relevant endpoints (inflammatory markers, liver enzymes, behavioral tests, histopathology) are measured.
|
| ADME/Pharmacokinetics |
Lactiflorin is orally active with favorable pharmacokinetic properties. It is absorbed after oral administration and distributed to various tissues, including the liver and brain. The compound undergoes metabolism, including deglycosylation and oxidation, and is eliminated primarily in urine and bile. Its pharmacokinetic profile is similar to that of paeoniflorin, which has been extensively studied. The compound is soluble in water and organic solvents.
|
| Toxicity/Toxicokinetics |
Toxicological data for lactiflorin are limited. Paeoniflorin and related compounds have been extensively studied and are generally considered to have low toxicity. No significant toxicity has been reported at therapeutic doses. High doses may cause mild gastrointestinal effects. Standard laboratory safety practices should be followed when handling this compound. It is intended for research use only.
|
| References | |
| Additional Infomation |
Lactiflorin is an organic heteropentacyclic compound with the molecular formula C23H26O10, isolated from various Paeonia species. It is a plant metabolite. Lactiflorin is a benzoic acid ester, an organic heteropentacyclic compound, a cyclic ketal, a cyclic ketone, and a bridged ring compound. (+)-Lactiflorin has been reported in Paeonia species (such as Paeonia grandiflora, Paeonia veitchii, and Paeonia suffruticosa), and relevant data are available.
Lactiflorin is a monoterpene glycoside and a derivative of paeoniflorin, the major bioactive constituent of Paeonia lactiflora (white peony root). Paeonia lactiflora has been used in traditional Chinese medicine for centuries, and paeoniflorin is known for its anti-inflammatory, immunomodulatory, hepatoprotective, and neuroprotective effects. Lactiflorin is used as a reference standard for quality control of Paeonia-containing products and as a research tool for studying the pharmacological activities of paeoniflorin derivatives. It is for research use only. |
| Molecular Formula |
C23H26O10
|
|---|---|
| Molecular Weight |
462.45
|
| Exact Mass |
462.152
|
| CAS # |
1361049-59-3
|
| PubChem CID |
14605198
|
| Appearance |
White to off-white solid
|
| LogP |
-0.5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
843
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@@]12[C@]3(C[C@@H]4[C@]3([C@H](O1)CC4=O)COC(=O)C5=CC=CC=C5)O[C@H]6[C@H](O2)[C@H]([C@@H]([C@H](O6)CO)O)O
|
| InChi Key |
AGRYIZUKIKYUFX-DNITZUGTSA-N
|
| InChi Code |
InChI=1S/C23H26O10/c1-21-23(33-20-18(32-21)17(27)16(26)14(9-24)30-20)8-12-13(25)7-15(31-21)22(12,23)10-29-19(28)11-5-3-2-4-6-11/h2-6,12,14-18,20,24,26-27H,7-10H2,1H3/t12-,14+,15+,16+,17-,18+,20-,21+,22-,23-/m0/s1
|
| Chemical Name |
[(1R,3S,5R,6S,7S,8R,10R,12R,15R,17R)-6,7-dihydroxy-5-(hydroxymethyl)-10-methyl-14-oxo-2,4,9,11-tetraoxapentacyclo[10.4.1.01,10.03,8.015,17]heptadecan-17-yl]methyl benzoate
|
| Synonyms |
Lactiflorin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (216.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1624 mL | 10.8120 mL | 21.6240 mL | |
| 5 mM | 0.4325 mL | 2.1624 mL | 4.3248 mL | |
| 10 mM | 0.2162 mL | 1.0812 mL | 2.1624 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
